Baillie Gifford & CO Ab Cellera Biologics Inc. Transaction History
Baillie Gifford & CO
- $126 Billion
- Q1 2024
A detailed history of Baillie Gifford & CO transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 23,180,089 shares of ABCL stock, worth $68.6 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
23,180,089
Previous 24,044,796
3.6%
Holding current value
$68.6 Million
Previous $137 Million
23.52%
% of portfolio
0.08%
Previous 0.11%
Shares
13 transactions
Others Institutions Holding ABCL
# of Institutions
171Shares Held
120MCall Options Held
264KPut Options Held
254K-
Baker Bros. Advisors LP New York, NY27.5MShares$81.5 Million1.58% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$31.5 Million0.06% of portfolio
-
Capital World Investors Los Angeles, CA8.35MShares$24.7 Million0.01% of portfolio
-
Credit Suisse Ag Zurich, V84.55MShares$13.5 Million0.02% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.18MShares$12.4 Million0.43% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $844M
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...